Oncolytics Biotech Inc T.ONC

RE:Canaccord Fireside Chat & pelareorep's approval in mBC

[Noteable]

In December 2021 the following was posted:  ...

Ongoing challenges with ADCs include improving target specificity, optimizing the toxicity profile, and identifying biomarkers for patient selection.ONCY has been addressing the above challenges through pelareorep's clinical development plan that includes the AWARE-1 WOO study.

https://stockhouse.com/companies/bullboard/t.onc/?threadid=34185685

Repost from June 06, 2023

And then there is the matter of pelareorep boosting ADCs which Dr. Richard Vile stated would be very "synergistic"

So first Immune checkpoint inhibitors, then CAR-T and now ADCs. Those are the increasing wonders of pelareorep.

Pelareorep's ability to remodel an otherwise immunosuppressive tumor microenvironment (TME), along with pelareorep's ability to "prime"; the innate and adaptive immune system, and pelareorep's "fine boosting" capability are mechanisms that benefit the enhancement of both anti-body drug conjugates (ADC) and CAR-T therapies thus making both Pfizer and Roche significantly interested players in ONCY's potential acquisition.

https://stockhouse.com/companies/bullboard/t.onc/oncolytics-biotech-inc?threadid=35480000

Activating the Tumor Microenvironment

Both bispecific T-cell engagers and oncolytic viruses are promising cancer therapies, but the new research demonstrates that combining the two approaches could work even better. The researchers first administered oncolytic reovirus to both syngeneic murine and humanized tumor models, then injected the CD3-bispecific antibodies. The combined treatment induced strong tumor regression and prolonged survival compared to each treatment option individually.

Preconditioning the tumor microenvironment with oncolytic reovirus resulted in the activation of immunologically cold tumors, explained the researchers. This in turn led to more successful engagement of bispecific antibodies, causing tumor cell death.

"Since we found the T cells that entered the tumor after oncolytic virus treatment were virus-specific and not tumor-specific, we needed an original way to use these T cells for tumor killing" said Dr. van Montfoort.

"The bispecific antibodies allowed us to redirect them towards the tumor."

Reovirus and bispecific antibodies are a true tumor-killer combo that would not be effective without each other.

Up next, the researchers hope to move the combination of oncolytic viruses and bispecific antibodies to the clinic. They are now looking to replicate their success using human bispecific antibodies already in the pipeline for immunotherapy treatment of solid cancer tumors.

https://stockhouse.com/companies/bullboard/t.onc/oncolytics-biotech-inc?postid=35028009

Now ADCs have been formally recogized as another therapy for use in combination with ONCY's pelareorep

https://stockhouse.com/companies/bullboard/t.onc/oncolytics-biotech-inc?postid=35481265